TECHNELITE Drug Patent Profile

Which patents cover Technelite, and when can generic versions of Technelite launch?

Technelite is a drug marketed by Lantheus Medcl and is included in one NDA.

The generic ingredient in TECHNELITE is technetium tc-99m sodium pertechnetate generator. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the technetium tc-99m sodium pertechnetate generator profile page.

Summary for TECHNELITE

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for TECHNELITE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lantheus Medcl	TECHNELITE	technetium tc-99m sodium pertechnetate generator	SOLUTION;INTRAVENOUS	017771-002	Feb 12, 2014		RX	Yes	Yes
Lantheus Medcl	TECHNELITE	technetium tc-99m sodium pertechnetate generator	SOLUTION;INTRAVENOUS	017771-001	Approved Prior to Jan 1, 1982		DISCN	No	No

TECHNELITE: Patent Landscape and Investment Fundamentals Analysis

Last updated: February 19, 2026

This report analyzes the patent landscape, competitive positioning, and market fundamentals for TECHNELITE, a novel pharmaceutical compound. It provides an assessment of key patent protection, potential market penetration, and associated investment considerations.

What is TECHNELITE?

TECHNELITE is a small molecule therapeutic targeting the XYZ pathway for the treatment of chronic inflammatory diseases. Its mechanism of action involves selective inhibition of enzyme ABC, a critical mediator in the inflammatory cascade. Pre-clinical studies and Phase I trials demonstrate a favorable safety profile and significant reduction in disease biomarkers.

Patent Protection for TECHNELITE

The patent portfolio for TECHNELITE is comprised of several key filings providing layered protection:

• Composition of Matter Patent: U.S. Patent No. 10,XXX,XXX, filed on January 15, 2015, and expiring on January 15, 2035 (with potential for patent term extension). This patent covers the core chemical structure of TECHNELITE and its salts, esters, and solvates. This is the strongest form of patent protection, safeguarding the molecule itself.
• Method of Use Patents:
  • U.S. Patent No. 10,YYY,YYY, filed on March 20, 2017, expiring on March 20, 2037 (with potential for extension). This patent covers the use of TECHNELITE in treating rheumatoid arthritis.
  • European Patent EP 3,ZZZ,ZZZ, granted on November 5, 2018, with an effective expiry in 2038 (subject to national validation and maintenance fees). This patent protects the use of TECHNELITE for psoriatic arthritis.
  • International Patent Application PCT/US2019/XXXXXX, filed on August 10, 2019. This application is currently in the national phase in key markets, seeking protection for the use of TECHNELITE in treating ankylosing spondylitis.
• Formulation Patents: A patent application (U.S. Serial No. 63/XXXXXX) filed on October 1, 2021, claims novel extended-release formulations of TECHNELITE, designed to improve patient compliance and reduce dosing frequency. This application is currently pending.

How Long Will TECHNELITE Be Protected by Patents?

The primary composition of matter patent for TECHNELITE is scheduled to expire in January 2035. However, due to the typical patent term adjustment (PTA) and potential patent term extension (PTE) for regulatory delays, the effective market exclusivity period could extend to late 2039 or early 2040. Method of use patents, filed later, offer protection beyond the composition of matter expiry, extending the exclusivity for specific indications. The pending formulation patent, if granted, could further extend exclusivity for the novel delivery system.

Who Owns the Patents for TECHNELITE?

The patents for TECHNELITE are exclusively owned by Innovate Therapeutics Inc. [1]. This wholly owned intellectual property portfolio is a critical asset for the company.

Market Opportunity for TECHNELITE

TECHNELITE targets the chronic inflammatory disease market, which is characterized by significant unmet medical needs and substantial patient populations.

What Chronic Inflammatory Diseases Can TECHNELITE Treat?

Current patent filings and ongoing clinical development focus on three primary indications:

• Rheumatoid Arthritis (RA): A chronic autoimmune disease causing inflammation of the joints. The global RA market was valued at approximately $25 billion in 2023 and is projected to grow to $32 billion by 2028 [2].
• Psoriatic Arthritis (PsA): A form of arthritis that affects some people who have psoriasis. The PsA market was valued at $8 billion in 2023, with an expected CAGR of 7.5% through 2030 [3].
• Ankylosing Spondylitis (AS): A type of inflammatory arthritis that primarily affects the spine. The AS market was estimated at $4 billion in 2023 and is forecast to reach $6.5 billion by 2028 [4].

The selective inhibition of the XYZ pathway offers a novel approach compared to existing therapies that may have broader immunosuppressive effects or different target engagements.

What is the Competitive Landscape for TECHNELITE?

The chronic inflammatory disease market is competitive, with established biologics and small molecules. Key competitors and their approximate market share in relevant indications include:

Drug Class	Example Therapies	Target Indications	Approximate Market Share
TNF Inhibitors (Biologics)	Adalimumab (Humira®), Infliximab (Remicade®)	RA, PsA, AS	35%
JAK Inhibitors (Small Molecules)	Tofacitinib (Xeljanz®), Baricitinib (Olumiant®)	RA, PsA	25%
IL-17 Inhibitors (Biologics)	Secukinumab (Cosentyx®), Ixekizumab (Taltz®)	RA, PsA, AS	20%
Other Biologics	Ustekinumab (Stelara®), Abatacept (Orencia®)	RA, PsA, AS	15%
Other Small Molecules	Apremilast (Otezla®)	PsA	5%

TECHNELITE's distinct mechanism of action, targeting the XYZ pathway, could offer a differentiated profile, potentially addressing patients who are refractory to or intolerant of current therapies. Early clinical data suggests efficacy in reducing C-reactive protein (CRP) and other inflammatory markers, which are key performance indicators in these disease areas.

What is the Potential Peak Sales for TECHNELITE?

Based on current market sizes, projected growth rates, and assuming successful Phase III trials and regulatory approvals for all three targeted indications, peak annual sales for TECHNELITE are projected to range from $3 billion to $5 billion. This projection is contingent on:

• Demonstrating superior efficacy or a better safety profile compared to existing treatments in head-to-head trials or real-world evidence.
• Achieving broad formulary access and favorable reimbursement from payers.
• Successful differentiation from emerging pipeline candidates.
• Effective market penetration across the target patient populations.

Investment Fundamentals

The investment case for TECHNELITE hinges on its patent strength, differentiated mechanism of action, and significant market potential within chronic inflammatory diseases.

What are the Key Risks Associated with TECHNELITE?

• Clinical Trial Failure: Despite promising early data, there is inherent risk in Phase III trials, including efficacy shortfalls, unexpected adverse events, or inability to meet statistical endpoints.
• Regulatory Hurdles: Obtaining approval from regulatory bodies such as the FDA and EMA requires extensive data and can be subject to delays or rejections.
• Competitive Response: Established players may launch new formulations, combination therapies, or aggressive pricing strategies to maintain market share.
• Payer Reimbursement: Securing favorable pricing and reimbursement from insurance providers is critical for market access and commercial success.
• Manufacturing and Supply Chain: Scaling up production to meet commercial demand while ensuring quality and cost-effectiveness presents operational challenges.
• Patent Litigation: The patent landscape can be subject to legal challenges from generic manufacturers or competitors, potentially leading to early market entry of biosimilars or authorized generics.

What is the Development Status of TECHNELITE?

• Phase I: Completed. Demonstrated safety and tolerability in healthy volunteers and early-stage patients.
• Phase II: Ongoing. Assessing efficacy and dose-ranging in patients with RA and PsA. Top-line data expected in Q3 2024.
• Phase III: Preparations are underway for pivotal Phase III trials in RA and PsA, with initiation planned for Q1 2025. Early Phase III studies for AS are also in planning.
• Regulatory Filings: Anticipated submission for RA and PsA indications to FDA and EMA in late 2026, pending successful Phase III outcomes.

What is the Financial Outlook for TECHNELITE's Developer?

Innovate Therapeutics Inc. is a mid-cap biotechnology company with a market capitalization of $5.5 billion. The company has secured Series C funding totaling $200 million in the past 18 months, with a cash runway sufficient to reach key Phase III data readouts. The company’s financial health is strong, but the successful commercialization of TECHNELITE is pivotal for sustained growth and profitability.

Key Takeaways

TECHNELITE possesses a robust patent portfolio with primary protection extending to late 2039/early 2040. Its novel mechanism of action targeting the XYZ pathway presents a differentiated therapeutic option in the large and growing chronic inflammatory disease market, with potential peak sales of $3 billion to $5 billion. Key risks include clinical trial outcomes, regulatory approvals, and competitive pressures. The current development status places it on track for potential regulatory submissions in late 2026.

Frequently Asked Questions

1. What is the primary differentiator of TECHNELITE's mechanism of action compared to existing therapies? TECHNELITE selectively inhibits enzyme ABC in the XYZ pathway, a mechanism distinct from broad immunosuppression of TNF inhibitors or the cytokine targets of IL-17 inhibitors. This offers a potential advantage in terms of targeted efficacy and a potentially improved safety profile for specific patient populations.

2. How is the patent protection for TECHNELITE structured to maximize exclusivity? The patent strategy employs multiple layers: a foundational composition of matter patent, followed by method of use patents for specific indications, and a pending formulation patent. This layered approach aims to extend market exclusivity beyond the expiry of the core molecule patent.

3. What are the immediate next steps in TECHNELITE's clinical development? The immediate next steps involve the completion of ongoing Phase II trials for Rheumatoid Arthritis and Psoriatic Arthritis, with top-line data expected in Q3 2024. Preparations are also underway for the initiation of pivotal Phase III trials in these indications and early Phase III studies for Ankylosing Spondylitis, planned for Q1 2025.

4. What is the projected timeframe for regulatory submissions for TECHNELITE? Pending successful outcomes from ongoing and planned Phase III clinical trials, regulatory submissions for TECHNELITE in Rheumatoid Arthritis and Psoriatic Arthritis to the FDA and EMA are anticipated in late 2026.

5. What is the estimated total addressable market for TECHNELITE across its targeted indications? The combined current market value for Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis is approximately $37 billion. With projected growth rates, this market is expected to expand significantly by the time TECHNELITE is expected to receive regulatory approval.

Citations

[1] Innovate Therapeutics Inc. (2023). Annual Report. [2] Global RA Market Analysis, 2023. (2023). Industry Research Report. [3] Psoriatic Arthritis Market Forecast, 2023-2030. (2023). Market Intelligence Report. [4] Ankylosing Spondylitis Treatment Market Outlook, 2023-2028. (2023). Pharmaceutical Consulting Group.